![](https://www.diabetesnews.com/wp-content/uploads/2012/10/heart-rate-300x251-150x150.jpg)
The type 2 diabetes drug liraglutide could affect heart variability in newly diagnosed people who are overweight and have heart problems, according to new research. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist which helps control blood sugar levels and reduces post-meal hyperglycemia. The drug is marketed as Victoza and Saxenda.